OSS, the Netherlands– Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announced the appointment of Eduardo Bravo as Chief Executive Officer. Over the course of his extensive career in the biopharmaceutical sector, Mr. Bravo has held multiple CEO positions, including in the autoimmune space, and served as Chair on various Boards, guiding life science companies through different phases of corporate growth and leading successful transactions including financing rounds, strategic partnerships and acquisitions. In addition, Citryll has appointed Tim Schenk, Ph.D., as Chief Business Officer. Dr. Schenk brings with him a broad background in business and commercial development across the life sciences industry.
These appointments come at a key juncture for Citryll as the company has recently completed the healthy volunteer studies for its lead Neutrophil Extracellular Trap-targeting antibody, CIT-013, and is transitioning into the next stage of clinical development with the initiation of Phase 2 proof-of-concept trials in rheumatoid arthritis and hidradenitis suppurativa, which are planned for 2024. As Mr. Bravo steps into the CEO role, Eric Meldrum, Ph.D., will fully resume his position as Chief Scientific Officer at Citryll.
“Eduardo’s and Tim’s extensive experience will be extraordinarily valuable to the Citryll team. With the addition of these industry experts with strong track records, we have composed a leadership team that is well-positioned to successfully reach the next stage of clinical and corporate development for the company,” said Paul Peter Tak, M.D., Ph.D., FMedSci, Chair of Citryll’s Board of Directors. “We would like to thank Eric for leading the organization as interim CEO in addition to his CSO responsibilities and look forward to the whole team’s contributions for the upcoming Phase 2 proof-of-concept clinical trials.”
“Citryll’s profound understanding of the neutrophil extracellular trap pathway represents a unique opportunity to develop a new treatment modality for autoimmune and autoinflammatory diseases,” said Eduardo Bravo, CEO of Citryll. “I am excited to join this exceptional team and build on the extensive preclinical proof of concept and promising first in human clinical data to unravel the potential of CIT-013 in a range of immune-mediated inflammatory diseases.”
